The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy by Wilke, R. A. et al.
translation nature publishing group
112    VOLUME 92 NUMBER 1 | jULY 2012 | www.nature.com/cpt
Cholesterol reduction from statin therapy has been one of 
the greatest public health successes in modern medicine. 
Simvastatin is among the most commonly used prescription 
medications. A non-synonymous coding single-nucleotide 
 polymorphism (SNP), rs4149056, in SLCO1B1 markedly 
increases systemic exposure to simvastatin and the risk of mus-
cle toxicity. This guideline explores the relationship between 
rs4149056 (c.521T>C, p.V174A) and clinical outcome for all 
statins. The strength of the evidence is high for myopathy with 
simvastatin. We limit our recommendations accordingly.
Background
The purpose of this study was to provide interpretive guidance 
when SLCO1B1 genotype is already available in the clinical 
environment. We do not argue directly in this guideline that 
SLCO1B1 genotyping is absolutely necessary. However, it seems 
that the implementation of a gene-based dosing approach is 
inevitable. We therefore provide guidance for clinicians treating 
patients with simvastatin in the event that SLCO1B1 genotype 
is available during routine care.
This guideline is written for providers attempting to manage 
myopathy risk. Because the strength of the evidence is highest for 
simvastatin, we limit our recommendations accordingly. We do 
not present guidelines for all statins. Furthermore, our primary 
goal is to reduce muscle toxicity and optimize patient adherence. 
Although efficacy studies are under way, we do not yet see a clear 
basis for making recommendations on the role of SLCO1B1 geno-
type in lipid-lowering efficacy.
Focused Literature review
A systematic literature review was conducted that focused on 
SLCO1B1 gene polymorphisms and statin-related end points in 
humans. Emphasis was placed on the SLCO1B1 variant rs4149056 
and two primary end points: (i) statin pharmacokinetics (includ-
ing parent drugs, lactones, acids, and derivatives related to phase I 
oxidation and/or phase II conjugation) and (ii) relevant studies of 
clinical outcome. Because rs4149056 acts via its damaging effect 
on OATP1B1 protein function, it is assumed that other damag-
ing SLCO1B1 gene variants may have similar clinical impact. 
However, we limit our recommendations to rs4149056 because 
the vast majority of pharmacokinetic and clinical outcome data 
have been published for this variant only.
At present, our recommended approach does not include 
other pharmacokinetic genes. The quality of evidence linking 
other pharmacokinetic candidates to myopathy is low to moder-
ate, and additional study is needed. The evidence linking phar-
macodynamic candidates to statin-induced myopathy is sparse. 
The mechanism underlying this adverse drug reaction (ADR) 
is only partly understood. Although some data show promise 
in terms of identifying pharmacodynamic variants, the clinical 
utility of typing these variants remains unclear.
scope oF the proBLem
The first statin to be approved by the US Food and Drug 
Administration (FDA) was lovastatin in 1987, followed by 
simvastatin in 1988, pravastatin in 1991, fluvastatin in 1994, 
atorvastatin in 1997, cerivastatin in 1998, rosuvastatin in 2003, 
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and pitavastatin in 2009.1,2 Cerivastatin was withdrawn in 2001, 
because of its higher frequency of rhabdomyolysis. Seven of 
these agents remain in clinical use; and five are currently avail-
able as generic formulations (atorvastatin, fluvastatin, lovastatin, 
pravastatin, and simvastatin). In 2010, simvastatin was the most 
commonly prescribed generic statin formulation and the third 
most commonly prescribed drug in the United States (http://
www.pharmacytimes.com/publications/issue/2011/May2011/
Top-200-Drugs-of-2010).
In general, statins are safe. The most common statin-related 
ADR is skeletal muscle toxicity.3 Statin-related muscle problems 
include myalgias (pain), myopathy (pain with evidence of muscle 
degradation), and rhabdomyolysis (severe muscle damage with 
acute kidney injury). Frequency varies by definition, but, overall, 
statin-related myalgias are common, occurring in 1–5% of sub-
jects exposed. In patients without arthritis, National Health and 
Nutrition Examination Survey data suggest a “number needed 
to harm” of 17 (ref. 4).
Clinicians often measure serum creatine kinase (CK) lev-
els, as a rough proxy for severity, but the correlation between 
symptoms and CK level is incomplete. Therefore, the clinical 
interpretation of CK level is complex. Elevations less than 
threefold the upper limit of normal (ULN) are typically of 
little consequence. Conversely, clinicians often intervene 
(change dose or change drug) when CK levels exceed three-
fold the ULN. At present, the literature support three diagnos-
tic strata: (i) incipient myopathy (CK above 3-fold the ULN, 
less than 10-fold the ULN), (ii) myopathy (CK above 10-fold 
the ULN, less than 50-fold the ULN), and (iii) rhabdomyoly-
sis (CK above 50-fold the ULN).5,6 In the context of statin 
monotherapy, the frequency of myopathy is ~1/1,000, and 
the frequency of rhabdomyolysis is ~1/100,000. As discussed 
further below, frequency increases with dose.
cLinicaL determinants oF risk
Clinical factors known to influence a patient’s risk for develop-
ing statin-induced muscle toxicity include increased statin dose, 
advanced age, low body mass index, female gender, metabolic 
comorbidities (e.g., hypothyroidism), intense physical exercise, 
and Asian or African ancestry.3,7–10 Because polypharmacy is 
common in the elderly, the association with age is partly attribut-
able to drug–drug interactions as well as to increases in chronic 
renal or hepatic disease.11
After studying the medical records of more than 250,000 
patients, Schech et al. reported that statin users over age 65 years 
have four times the risk of hospitalization due to muscle toxicity 
than younger statin users (composite end point including myosi-
tis, myopathy, and/or rhabdomyolysis) (odds ratio (OR) 4.36; 
95% confidence interval (CI) = 1.5–14.1).12 Although contro-
versial, female gender may also increase risk because of smaller 
volumes of distribution.12,13 Although vigorous exercise often 
contributes to CK elevation in the context of statin exposure,14,15 
the impact of physical activity can be difficult to interpret. Even 
in the absence of drug exposure or underlying muscle pathol-
ogy, strenuous exercise can be associated with elevated serum 
CK levels exceeding 10-fold ULN.
Statin dose is the strongest independent predictor of risk. 
McClure and colleagues have reported an incidence rate for 
myotoxicity roughly sixfold higher in patients on high-dose 
statin therapy.16 Although the dose dependence of this rela-
tionship appears to be a class effect, a growing body of evidence 
suggests that the influence of dose may be greatest for simvas-
tatin.17 Therefore, in 2011 the FDA announced an update to the 
simvastatin product label recommending against initiation of 
the 80-mg dose and cautioning against continuation of an 80-mg 
dose unless the patient has already tolerated it without muscle 
problems for more than 1 year.
drug–drug interactions
In the context of statin monotherapy, myopathy rates are low.13 
The frequency of this ADR increases with coadministration of 
medications altering the pharmacokinetic handling of statins. 
Between 1998 and 2001, more than 40 cases of muscle toxicity 
associated with the use of cerivastatin were found to be fatal. 
Many of these occurred within the context of use of gemfibrozil, 
a drug that strongly inhibits the cytochrome P450 (CYP) 2C8-
catalyzed biotransformation of cerivastatin and also inhibits 
membrane transport and phase II conjugation of statins.18,19
The biological disposition of this class of drugs differs on a 
drug-by-drug basis. Some statins (atorvastatin, fluvastatin, 
lovastatin, and simvastatin) undergo extensive phase I oxida-
tion; others (pitavastatin, pravastatin, and rosuvastatin) do not. 
CYP3A4 inhibitors (e.g., azole antifungals, protease inhibitors, 
amiodarone, and many calcium channel blockers) increase risk 
of myopathy for statins metabolized by CYP3A4/5 (e.g., simv-
astatin, lovastatin, and atorvastatin).20
Many statins also undergo additional modification 
through phase II conjugation by enzymes in the UDP-
glucuronosyltransferase-1 (UGT1) family. This process can 
be altered by concomitant administration of fibric acids.21 
Gemfibrozil, a fibric acid derivative, alters pharmacokinetic 
handling of a variety of statins. By inhibiting the glucuronida-
tion and membrane transport of simvastatin hydroxy acids, 
gemfibrozil increases systemic exposure to active simvastatin 
acid,22 placing patients at increased risk for developing myopa-
thy. Because of interactions such as these, the FDA label update 
also recommends reducing the dose of simvastatin in patients 
using concomitant medications known to alter its pharmacoki-
netics (details in Supplementary Table S1 online).
Slco1b1
OATP1B1 ( encoded by SLCO1B1) facilitates the hepatic uptake 
of statins as well as numerous endogenous compounds (e.g., 
bilirubin and 17-beta-glucuronosyl estradiol).23,24 Changes 
in the activity of this transporter (as occur during drug–drug 
interaction) can markedly increase the severity of statin-related 
muscle damage. For example, cyclosporine, a strong inhibitor of 
CYP3A4 and OATP1B1, increases the area under the curve for 
simvastatin acid three- to eightfold.24
Beyond acquired inhibition, genetic variability in SLCO1B1 
also alters plasma concentration of statins. The overall pharma-
cokinetic profiles appear to be altered more for simvastatin than 
translation
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for any other drug in the class.24,25 Other transporters poten-
tially influencing the distribution and tissue uptake of statins 
include OATP1B3 (encoded by SLCO1B3), OATP2B1 (encoded 
by SLCO2B1), OATP1A2 (encoded by SLCO1A2), and sodium-
dependent taurocholate cotransporting polypeptide, NTCP.23,24
nomencLature
The SLCO1B1 gene locus occupies 109 kb on chromosome 12 
(Chr 12p12.2). Although many single-nucleotide polymorphisms 
(SNPs) have been identified in SLCO1B1, only a few are known 
to have functional effects.24,26 The common c.521T>C variant 
rs4149056 produces a p.V174A substitution. The minor C allele 
at this locus has been associated with decreased transport func-
tion in vitro27,28 and decreased clearance for a number of drugs 
in vivo.29–31 Assignment of OAT1B1 phenotype has been sum-
marized in Table 1, based on rs4149056. In general, this variant 
is present at a minor allele frequency between 5 and 20% in most 
populations (see Supplementary Tables S2–S4 online).
SLCO1B1 alleles are often named using *nomenclature, rep-
resenting various SNPs alone or in combination (http://www.
pharmgkb.org/gene/PA134865839#tabview=tab4&subtab=3
3). SLCO1B1 haplotypes are listed in Supplementary Table S2 
online, including additional variants that are associated with low 
OAT1B1 protein expression or function. The minor C allele at 
rs4149056 is contained within SLCO1B1*5 (rs4149056 alone) as 
well as the *15, *16, and *17 haplotypes. As explained in detail 
below, although rs4149056 clearly influences the pharmacoki-
netic handling of simvastatin acid, the magnitude of this effect 
is similar for the *5, *15,*16, and *17 haplotypes.31
rs4149056 and statin kinetics
Simvastatin is administered as an inactive lactone, and hydrolyzed 
in vivo to the corresponding hydroxy acid by nonspecific carbox-
yesterases. Simvastatin acid is a potent inhibitor of HMG-CoA 
reductase. Simvastatin and lovastatin are the only statins requiring 
bioactivation. All other statins are administered directly as bio-
active acid salts. For example, atorvastatin is administered in an 
active form (atorvastatin acid), and extensive first-pass metabo-
lism by CYP3A4/5 yields ortho- and para-hydroxylated deriva-
tives with similar activity to the parent compound.
SLCO1B1 polymorphisms clearly impact the pharmacokinet-
ics of simvastatin and, to a lesser degree, the pharmacokinetics 
of other statins (Supplementary Table S5, online).32 Pasanen 
et al. determined that homozygous carriers of the C allele at 
rs4149056 (CC genotype) had much greater exposure to the 
active simvastatin acid (AUC0-12) than subjects homozygous for 
the ancestral T allele.31 In single-dose studies (Supplementary 
Figure S1 online), the observed plasma areas under the curve 
of active simvastatin acid, pitavastatin, atorvastatin, pravasta-
tin, and rosuvastatin have been, respectively, 221, 162–191, 144, 
57–130, and 62–117% higher in rs4149056 CC homozygotes 
than in rs4149056 TT homozygotes.
rs4149056 and myopathy risk
In 2008, the SEARCH Collaborative Group (Study of the 
Effectiveness of Additional Reductions in Cholesterol and 
Homocysteine) conducted a case–control study of simvastatin-
induced myopathy using archived DNA from a randomized trial 
including more than 12,000 subjects who had received either 
low-dose simvastatin (20 mg daily) or high-dose simvastatin 
(80 mg daily) after myocardial infarction.17 During the course of 
the trial, 49 subjects in the high-dose arm developed myopathy 
(CK > 10-fold the ULN with pain). An additional 49 subjects in 
the same treatment arm developed “incipient” myopathy (CK 
> threefold the ULN and five times the patient’s baseline level). 
Of these combined incipient and definite myopathy cases, 85 
underwent whole-genome scanning (with a platform containing 
317,000 SNPs), and the results were compared with genome-
wide data from 90 nonmyopathic controls (frequency-matched 
from within the same treatment arm). A single-nucleotide vari-
ant survived statistical correction for multiple testing: a base 
substitution in the SLCO1B1 gene. After genomic resequencing, 
the putative causative allele rs4149056 was retested for associa-
tion in a subset of definite myopathy cases from the original 
cohort, revealing an OR for myopathy of 4.5 per copy of the 
minor C allele.17 Because ~25% of the general population are 
carriers of this allele, and 1/100 patients taking high-dose sim-
vastatin have an ADR, approximately 30 subjects would need to 
be genotyped to avoid one ADR.
The finding of an association between rs4149056 and sta-
tin-induced muscle toxicity has since been replicated in both 
a second independent trial and a practice-based longitudinal 
cohort. The Heart Protection Study enrolled more than 20,000 
subjects with known vascular disease, or vascular risk factors 
and randomized each study participant to either 40 mg simva-
statin daily or placebo.33,34 Twenty-four cases of myopathy 
(10 definite and 14 incipient) were identified from among 
the 10,269 participants receiving 40 mg of simvastatin, and 
21 of these cases later underwent retrospective genotyping for 
rs4149056.17 In this validation cohort, the relative risk was 2.6 
per copy of the minor C allele.17 Although both the SEARCH 
trial and the Heart Protection Study represent randomized 
table 1 assignment of likely Slco1b1 phenotype based on genotype
genotype definitions Diplotypes observed genotype at rs4149056 observed phenotype
An individual carrying two  
functional alleles
*1/*1 TT Homozygous wild-type or normal 
(55–88% of patients) high activity
An individual carrying one functional 
allele plus one reduced-function allele
*1/*5 (or *1/*15, *1/*16, or *1/*17) TC Heterozygous (11–36% of patients)
intermediate activity
An individual carrying two  
reduced-function alleles
*5/*5 (or *5/*15, *5/*16, *5/*17, 
*15/*15, *15/*16, *15/*17, *16/*16, 
*16/*17, or *17/*17)
CC Homozygous variant or mutant (0–6% of 
patients) low activity
translation
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controlled treatment trials, the effect size for rs4149056 was 
lower in the latter (i.e., at the 40-mg dose) than in SEARCH (i.e., 
at the 80-mg dose), underscoring the importance of dose.
Practice-based data suggest that the association between 
rs4149056 and muscle toxicity is stronger for simvastatin than 
for other drugs within the class. The C allele at rs4149056 has 
recently been shown to influence the rate of medication adherence 
for simvastatin.35 In the STRENGTH study, 509 hypercholeste-
rolemic patients were randomized to simvastatin, atorvastatin, 
or pravastatin and followed for 16 weeks. The primary end point 
of the study was a composite of study drug discontinuation for 
any adverse effect, myalgia or muscle cramping, and/or elevated 
serum CK levels more than threefold the ULN. The overall effect 
size was striking for simvastatin (OR: 2.8, 95% CI: 1.3–6.0) but 
rather modest for atorvastatin (OR 1.6, 95% CI: 0.7–3.7). No sig-
nificant association was observed for pravastatin (OR 1.0, 95% CI: 
0.4–2.6). As in the STRENGTH study, other groups have reported 
a modest association between rs4149056 and atorvastatin intoler-
ance based on adverse muscle symptoms,36 but the association 
between rs4149056 and laboratory-confirmed myopathy has been 
less compelling for atorvastatin.37
From the medical records of nearly 9,000 patients followed 
in an academic lipid clinic, Brunham and colleagues identified 
25 laboratory-confirmed myopathy cases (frequency 0.26%).37 
All 25 cases were genotyped for rs4149056, along with drug-
exposed controls (frequency-matched 2:1), revealing an OR for 
myopathy of 2.3 per copy of the minor C allele at rs4149056. The 
OR was highest, 3.2 (95% CI 0.83–11.96), for subjects with the 
CC genotype exposed to simvastatin. No such relationship was 
observed using a similar number of atorvastatin cases (OR 1.06, 
95% CI 0.22–4.80).37 These observations are consistent with 
reported differences in clearance (Supplementary Figure S1 
online). To date, there is little evidence that rs4149056 genotype 
influences symptomatic intolerance or myopathy for pravasta-
tin35 or rosuvastatin.36 Hence, the observed clinical association 
between rs4149056 and myopathy may not be a class effect.
avaiLaBLe genetic-test options
The commercially available clinical testing options listed in 
the Supplementary Material online and are freely available at 
http://www.PharmGKB.org. The rs4149056 SNP can be geno-
typed alone (e.g., PCR-based single SNP assay) or multiplexed on 
a variety of array-based platforms (e.g., with other pharmacoki-
netic variants). Array-based technologies are readily available 
within a Clinical Laboratory Improvement Amendments–
approved environment for the Illumina VeraCode ADME 
array or the DMET Plus Affymetrix array. See Supplementary 
Material for details. This variant is also among the pharmaco-
genetic content available for participants in direct-to-consumer 
genomic offerings (e.g., 23andMe.com).
incidentaL Findings
Genetic variability in SLCO1B1 influences the hepatic uptake of 
other drugs (e.g., methotrexate)26 as well as important endog-
enous compounds (e.g., bilirubin)38 (Supplementary Material 
online).
gene-Based dosing recommendations
For simvastatin, the evidence linking myopathy to rs4149056 
in SLCO1B1 is of high quality, and this association has been 
reproduced in randomized trials and clinical practice–based 
cohorts. Conversely, the association of rs4149056 with myopa-
thy has been less compelling for other statins. We therefore focus 
this guideline on simvastatin. Our recommended approach 
(Table 2 and Figure 1) begins with product-label changes 
recently implemented by the FDA. (The agency’s recommen-
dations are further summarized in Supplementary Table S1 
online.) Decision-support tools are already being used to direct 
providers away from initiating the 80-mg simvastatin dose. At 
many of our institutions, SLCO1B1 genotype is further used to 
underscore this warning (i.e., myopathy risk for 80 mg of sim-
vastatin) for subjects with a C allele at rs4149056 (see details in 
Supplementary Material).
At lower simvastatin doses (e.g., 40 mg daily), it is our position 
that this information should be used to warn providers about 
modest increases in myopathy risk for subjects with a C allele at 
rs4149056 (Figure 1). Under these circumstances, we also high-
light the potential utility of routine CK surveillance (Table 2). 
If subjects with a C allele at rs4149056 do not achieve optimal 
low-density lipoprotein cholesterol–lowering efficacy with a 
table 2 dosing recommendations for simvastatin, when rs4149056 genotype (or phenotype) is available
genotype at 
rs4149056 anticipated phenotype implications for simvastatin Dosing recommendations for simvastatina
Classification of  
the recommendationb
TT Normal activity Normal myopathy risk FDA recommends against 80 mg (unless already 
tolerated 12 months). Prescribe desired starting 
dose and adjust doses of simvastatin based on 
disease-specific guidelines.
Strong
TC Intermediate activity Intermediate myopathy risk FDA recommends against 80 mg. Consider a 
lower dose; if suboptimal efficacy, consider an 
alternative statin.
Strong
CC Low activity High myopathy risk FDA recommends against 80 mg. Prescribe a 




aIn all cases, the potential for drug–drug interaction should be evaluated prior to initiating a prescription. bSee supplementary  materials (text section entitled “Levels of 
Evidence”) online for additional details regarding the three-tiered system used to grade the quality of evidence. Further information is available within ref. 41.
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lower dose of simvastatin, we recommend that the prescribing 
physician consider an alternative statin based on (i) potency dif-
ferences, (ii) kinetic differences, (iii) comedications, (iv) hepatic 
function, (v) renal function, and (vi) relevant comorbidities.
potentiaL BeneFits and risks For the patient
Statins have a wide therapeutic index,39 and severe ADRs are 
therefore relatively uncommon. Nonetheless, even though the 
myopathy rate is low, the high prevalence of the clinical indica-
tion (hypercholesterolemia and cardiovascular disease) creates 
a situation in which the absolute number of ADRs is substantial. 
Furthermore, in the absence of severe myopathy, many patients 
still opt to discontinue statin therapy because of intermedi-
ate toxicity, and statin nonadherence thus has the potential to 
increase the burden of cardiovascular disease on our health-care 
infrastructure. It is with this perspective, a goal toward optimiz-
ing adherence, that we present the current guideline.
caveats: appropriate use and/or potentiaL misuse 
oF genetic tests
For the 40-mg simvastatin dose, the relative risk of myopathy is 
2.6 per copy of the C allele at rs4149056. The risk is even higher 
for the 80-mg simvastatin dose (myopathy OR 4.5 for TC geno-
type, ~20.0 for CC genotype). Nonetheless, simvastatin-related 
muscle toxicity can still occur in the absence of rs4149056. Thus, 
a TT genotype does not imply the absence of another potentially 
deleterious variant in SLCO1B1 or elsewhere. Furthermore, 
because rs4149056 can also be inherited in combination with 
other SLCO1B1 gene variants known to have protective effects, 
it should not be presumed that the C allele at rs4149056 confers 
risk with 100% certainty.
current state oF impLementation
Many academic medical centers have on-site array-based SNP 
genotyping available within a Clinical Laboratory Improvement 
Amendments–approved environment, and some have the capa-
bility to link this information directly to an electronic medi-
cal record.40 Few, however, integrate this information into the 
medical record preemptively; that is, before onset of the clinical 
indication requiring the drug. At present, there is no uniform 
approach to implementation of this information, but several 
institutions have begun providing automated decision support 
(examples provided in the Supplementary Material online).
suppLementary materiaL is linked to the online version of the paper at 
http://www.nature.com/cpt
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Figure 1 PREDICT (Pharmacogenomics Resource for Enhanced Decisions in Clinical Care and Treatment) decision support algorithm for simvastatin. 
Algorithm activated by provider selection of any simvastatin dose during the process of electronic prescribing at Vanderbilt University Medical Center.  
CK, creatine kinase.
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